TP53 and renal cell carcinoma: In fact, a comparative evaluation of RCC subtypes reported that, among the aforementioned SMGs, only TP53 and PTEN were seen in all conventional subtypes (ccRCC, pRCC, and chRCC), yet they maintained differential, RCC subtype-specific, prognostic value, i.e., TP53 mutation associated reduced survival rates for ccRCCs and pRCCs, whereas PTEN mutation only associated reduced survival rates for chRCCs [62].